Non-adherence assessment to immunosuppressant therapy with a self-report questionnaire and intra-patient variability in renal transplantation: risk factors and clinical correlations.


Journal

Minerva urology and nephrology
ISSN: 2724-6442
Titre abrégé: Minerva Urol Nephrol
Pays: Italy
ID NLM: 101777299

Informations de publication

Date de publication:
Feb 2023
Historique:
pubmed: 31 3 2021
medline: 22 2 2023
entrez: 30 3 2021
Statut: ppublish

Résumé

Non-adherence (NA) to immunosuppressive drugs is to date considered a crucial issue in kidney transplanted patients (KTRs), leading to de-novo donor-specific anti-HLA antibodies (dnDSA) development, acute and chronic rejection, and at least graft loss. However, NA assessment is challenging, often leading to underestimation in real-life settings. NA evaluation in all KTRs referred to our post-transplantation clinic in the period between 01/01-15/07/2018 with self-report questionnaire combined to intra-patient variability (IPV) of the pivotal immunosuppressive drug (based on trough levels of tacrolimus/mTOR inhibitor). Based on both questionnaire and IPV, 86 out of the 504 tested KTRs (17%) were classified as NA. Male gender (OR, 2.0; 95% confidence interval [CI], 1.2 to 3.4), high educational level (OR for KTRs with a degree, 1.8 [95% CI, 1.0 to 3.1]), employment (OR, 2.0 [95% CI, 1.2 to 3.3]), young age at transplantation (P=0.017), longer time on the waiting list and after transplantation (P=0.027 and 0.049 respectively) were all associated with NA. High IPV was mostly documented in KTRs treated with the twice-daily formulation of the immunosuppressive drug (OR, 1.5 [95% CI, 1.0 to 2.1]) and better associated with dnDSA appearance (OR, 2.1 [95% CI, 1.1 to 3.9]). NA is a significant problem, difficult to assess, and can lead to dnDSA development also in our population. Identifying risk factors for NA might be an underestimated tool to improve graft and patient outcome in KTRs.

Sections du résumé

BACKGROUND BACKGROUND
Non-adherence (NA) to immunosuppressive drugs is to date considered a crucial issue in kidney transplanted patients (KTRs), leading to de-novo donor-specific anti-HLA antibodies (dnDSA) development, acute and chronic rejection, and at least graft loss. However, NA assessment is challenging, often leading to underestimation in real-life settings.
METHODS METHODS
NA evaluation in all KTRs referred to our post-transplantation clinic in the period between 01/01-15/07/2018 with self-report questionnaire combined to intra-patient variability (IPV) of the pivotal immunosuppressive drug (based on trough levels of tacrolimus/mTOR inhibitor).
RESULTS RESULTS
Based on both questionnaire and IPV, 86 out of the 504 tested KTRs (17%) were classified as NA. Male gender (OR, 2.0; 95% confidence interval [CI], 1.2 to 3.4), high educational level (OR for KTRs with a degree, 1.8 [95% CI, 1.0 to 3.1]), employment (OR, 2.0 [95% CI, 1.2 to 3.3]), young age at transplantation (P=0.017), longer time on the waiting list and after transplantation (P=0.027 and 0.049 respectively) were all associated with NA. High IPV was mostly documented in KTRs treated with the twice-daily formulation of the immunosuppressive drug (OR, 1.5 [95% CI, 1.0 to 2.1]) and better associated with dnDSA appearance (OR, 2.1 [95% CI, 1.1 to 3.9]).
CONCLUSIONS CONCLUSIONS
NA is a significant problem, difficult to assess, and can lead to dnDSA development also in our population. Identifying risk factors for NA might be an underestimated tool to improve graft and patient outcome in KTRs.

Identifiants

pubmed: 33781021
pii: S2724-6051.21.04244-2
doi: 10.23736/S2724-6051.21.04244-2
doi:

Substances chimiques

Immunosuppressive Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

92-98

Auteurs

Alberto Mella (A)

Division of Nephrology Dialysis and Transplantation, Department of Medical Sciences, "A. Vercellone" Renal Transplantation Center, Città della Salute e della Scienza, Turin, Italy.

Maria C Torazza (MC)

Division of Nephrology Dialysis and Transplantation, Department of Medical Sciences, "A. Vercellone" Renal Transplantation Center, Città della Salute e della Scienza, Turin, Italy.

Daniela Finocchietti (D)

Division of Nephrology Dialysis and Transplantation, Department of Medical Sciences, "A. Vercellone" Renal Transplantation Center, Città della Salute e della Scienza, Turin, Italy.
Department of Nephrology and Dialysis, Maggiore Hospital, Chieri, Turin, Italy.

Fabrizio Fop (F)

Division of Nephrology Dialysis and Transplantation, Department of Medical Sciences, "A. Vercellone" Renal Transplantation Center, Città della Salute e della Scienza, Turin, Italy.

Anna Allesina (A)

Division of Nephrology Dialysis and Transplantation, Department of Medical Sciences, "A. Vercellone" Renal Transplantation Center, Città della Salute e della Scienza, Turin, Italy.

Caterina Dolla (C)

Division of Nephrology Dialysis and Transplantation, Department of Medical Sciences, "A. Vercellone" Renal Transplantation Center, Città della Salute e della Scienza, Turin, Italy.

Roberta Giraudi (R)

Division of Nephrology Dialysis and Transplantation, Department of Medical Sciences, "A. Vercellone" Renal Transplantation Center, Città della Salute e della Scienza, Turin, Italy.

Luigi Biancone (L)

Division of Nephrology Dialysis and Transplantation, Department of Medical Sciences, "A. Vercellone" Renal Transplantation Center, Città della Salute e della Scienza, Turin, Italy - luigi.biancone@unito.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH